https://mindmedicinelaw.com/briefing/oral-ketamine-safety-review-implications-for-clinical-use-20260530-8592The Psychedelic Journalen2026-05-31T15:04:42.126538+00:00Oral Ketamine Safety Review: Implications for Clinical Useoral ketamine, safety profile, mental health treatment, clinical trials, policy decisions, ketamine risks, psychedelic therapieshttps://mindmedicinelaw.com/briefing/psilocybin-therapy-s-impact-on-anxiety-a-systematic-review-20260529-8488The Psychedelic Journalen2026-05-31T15:05:03.726196+00:00Psilocybin Therapy's Impact on Anxiety: A Systematic Reviewpsilocybin-assisted psychotherapy, anxiety treatment, systematic review, meta-analysis, clinical trials, psychedelic therapy, mental health, 5-HT2A receptor, study heterogeneity, psychotherapyhttps://mindmedicinelaw.com/briefing/nmda-antagonists-and-affective-biases-in-depression-treatment-20260529-8536The Psychedelic Journalen2026-05-31T15:04:56.108585+00:00NMDA Antagonists and Affective Biases in Depression TreatmentNMDA antagonists, affective biases, major depressive disorder, ketamine, pharmacodynamics, ion trapping, clinical trials, rats, neuroscience, antidepressant efficacyhttps://mindmedicinelaw.com/briefing/ketamine-for-depression-in-cancer-systematic-review-insights-20260529-8538The Psychedelic Journalen2026-05-31T15:04:49.538554+00:00Ketamine for Depression in Cancer: Systematic Review Insightsketamine, depression, cancer patients, systematic review, rapid antidepressant, clinical trials, long-term safety, treatment adherence, oncology, mental healthhttps://mindmedicinelaw.com/briefing/epa-s-snurs-impact-on-psychedelic-research-and-industry-20260529-7833The Psychedelic Journalen2026-05-30T22:04:17.771848+00:00EPA's SNURs Impact on Psychedelic Research and IndustryEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, environmental protection, chemical safety, industry impact, notification requirementshttps://mindmedicinelaw.com/briefing/integrative-approaches-in-clinical-psychology-future-trends-20260529-8168The Psychedelic Journalen2026-05-30T22:04:09.711837+00:00Integrative Approaches in Clinical Psychology: Future Trendsclinical psychology, psychotherapy, pharmacological treatments, integrative therapy, mental health care, psychedelic therapies, biopsychosocial model, combination therapy, treatment efficacy, personalized carehttps://mindmedicinelaw.com/briefing/omb-s-proposed-revisions-impacting-psychedelic-research-funding-20260529-7814The Psychedelic Journalen2026-05-30T22:04:01.549962+00:00OMB's Proposed Revisions Impacting Psychedelic Research FundingOMB revisions, federal financial assistance, psychedelic research funding, transparency and accountability, grant management, compliance standards, research implications, administrative burden, funding opportunitieshttps://mindmedicinelaw.com/briefing/protocatechuic-acid-s-neuroprotective-role-in-neurology-20260529-8203The Psychedelic Journalen2026-05-30T22:03:53.921225+00:00Protocatechuic Acid's Neuroprotective Role in Neurologyprotocatechuic acid, neuroprotection, Alzheimer's disease, Parkinson's disease, neuroinflammation, oxidative stress, clinical applications, neurological disorders, multi-target mechanisms, translational potentialhttps://mindmedicinelaw.com/briefing/ketamine-in-addiction-treatment-ethical-and-clinical-insights-20260529-8440The Psychedelic Journalen2026-05-30T22:03:45.180274+00:00Ketamine in Addiction Treatment: Ethical and Clinical Insightsketamine, addiction treatment, clinical trials, ethical considerations, NMDA receptor, substance use disorders, controlled substances, therapeutic protocols, patient safety, long-term effectshttps://mindmedicinelaw.com/briefing/ketamine-for-depression-in-cancer-patients-systematic-review-insights-20260529-8216The Psychedelic Journalen2026-05-30T15:04:56.922663+00:00Ketamine for Depression in Cancer Patients: Systematic Review Insightsketamine, depression, cancer patients, systematic review, rapid-acting antidepressant, treatment-resistant depression, clinical trials, long-term safety, psycho-oncology, dosing strategieshttps://mindmedicinelaw.com/briefing/pharmacokinetics-of-psychedelics-new-insights-from-systematic-review-20260529-8202The Psychedelic Journalen2026-05-30T15:04:47.420844+00:00Pharmacokinetics of Psychedelics: New Insights from Systematic Reviewpsychedelic pharmacokinetics, LSD, psilocybin, DMT, mescaline, 5-MEO-DMT, clinical trials, serotonergic psychedelics, dosing regimens, safety profileshttps://mindmedicinelaw.com/briefing/ketamine-for-depression-in-cancer-systematic-review-insights-20260529-8215The Psychedelic Journalen2026-05-30T15:04:37.876973+00:00Ketamine for Depression in Cancer: Systematic Review Insightsketamine, depression, cancer patients, systematic review, rapid antidepressant, clinical trials, mental health, oncology, treatment adherence, long-term safetyhttps://mindmedicinelaw.com/briefing/meta-analysis-reveals-mania-risks-in-psychedelic-use-20260529-8235The Psychedelic Journalen2026-05-30T15:04:28.355948+00:00Meta-analysis Reveals Mania Risks in Psychedelic Usepsychedelic research, hypomania risks, mania risks, clinical trials, patient screening, psychedelic-assisted therapy, serotonin receptors, mood disorders, therapeutic guidelines, neurochemical pathwayshttps://mindmedicinelaw.com/briefing/colorado-expands-natural-medicine-health-act-with-ibogaine-20260529-8281The Psychedelic Journalen2026-05-30T15:04:20.676355+00:00Colorado Expands Natural Medicine Health Act with Ibogainecolorado, natural medicine health act, ibogaine, psychedelic policy, substance use disorder, psychedelic research, clinical trials, regulation, therapeutic use, safety concernshttps://mindmedicinelaw.com/briefing/va-initiates-mdma-therapy-trial-for-ptsd-and-alcohol-use-20260529-8188The Psychedelic Journalen2026-05-30T15:04:10.350755+00:00VA Initiates MDMA Therapy Trial for PTSD and Alcohol UseMDMA therapy, VA clinical trial, PTSD treatment, alcohol use disorder, psychedelic research, veterans mental health, federal agency involvement, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/review-of-ketamine-pharmacokinetics-published-by-ncbi-20260529-8098The Psychedelic Journalen2026-05-29T22:04:46.883186+00:00Review of Ketamine Pharmacokinetics Published by NCBIketamine pharmacokinetics, intramuscular administration, clinical dosing strategies, psychiatric treatment, therapeutic outcomes, metabolism of ketamine, clinical research, psychedelic medicine, personalized medicine, public health implicationshttps://mindmedicinelaw.com/briefing/pharmacokinetics-of-psychedelics-implications-for-clinical-use-20260529-8093The Psychedelic Journalen2026-05-29T22:03:58.142038+00:00Pharmacokinetics of Psychedelics: Implications for Clinical Usepsychedelic pharmacokinetics, serotonergic psychedelics, clinical trials, LSD, psilocybin, DMT, therapeutic use, FDA guidelines, safety data, personalized medicinehttps://mindmedicinelaw.com/briefing/va-launches-mdma-trial-psilocybin-shows-lasting-effects-20260529-8122The Psychedelic Journalen2026-05-29T22:03:48.161550+00:00VA Launches MDMA Trial; Psilocybin Shows Lasting EffectsMDMA trial, psilocybin effects, Veterans Affairs, PTSD treatment, psychedelic therapy, mental health, clinical trials, antidepressant effects, psychedelic research, federal policyhttps://mindmedicinelaw.com/briefing/translational-research-in-psychedelic-therapies-new-frameworks-20260528-8546The Psychedelic Journalen2026-05-31T15:05:20.036727+00:00Translational Research in Psychedelic Therapies: New Frameworkstranslational research, psychedelic therapies, compound race pathology, ketamine, psilocybin, treatment-resistant depression, clinical trials, adaptive methodologies, multi-scale interventions, trial-design templateshttps://mindmedicinelaw.com/briefing/new-trial-design-templates-for-psychedelic-interventions-20260528-8549The Psychedelic Journalen2026-05-31T15:05:12.264077+00:00New Trial-Design Templates for Psychedelic Interventionspsychedelic interventions, clinical trial design, treatment-resistant depression, ketamine, psilocybin, autoimmune pathologies, long COVID, translational research, precision medicine, substrate-vector profilinghttps://mindmedicinelaw.com/briefing/ketamine-s-safety-and-addiction-risks-in-depression-treatment-20260528-7964The Psychedelic Journalen2026-05-30T22:04:25.088667+00:00Ketamine's Safety and Addiction Risks in Depression Treatmentketamine, depression treatment, addiction risk, clinical trials, mental health, FDA, NMDA receptor, esketamine, psychiatric treatment, public healthhttps://mindmedicinelaw.com/briefing/psilocybin-induced-syncope-in-clinical-trials-a-case-study-20260528-7887The Psychedelic Journalen2026-05-29T22:04:10.378207+00:00Psilocybin-Induced Syncope in Clinical Trials: A Case Studypsilocybin, neurocardiogenic syncope, clinical trials, cardiovascular monitoring, adverse events, psychedelic research, FDA approval, safety protocols, autonomic arousal, hypotensive eventshttps://mindmedicinelaw.com/briefing/sert-blockade-diminishes-4-meo-mipt-s-psychedelic-effects-20260527-7854The Psychedelic Journalen2026-05-29T22:04:35.602266+00:00SERT Blockade Diminishes 4-MeO-MiPT's Psychedelic Effects4-MeO-MiPT, SERT blockade, 5-HT2A agonist, psychedelic research, therapeutic psychedelics, serotonin transporter, clinical trials, pharmacology, psychoactive profiles, neurosciencehttps://mindmedicinelaw.com/briefing/psychedelics-antidepressant-mechanisms-via-gpcrs-20260527-8099The Psychedelic Journalen2026-05-29T22:04:19.002036+00:00Psychedelics' Antidepressant Mechanisms via GPCRspsychedelics, G Protein-Coupled Receptors, antidepressant effects, clinical research, biochemical pathways, depression treatment, psilocybin, LSD, mental health, drug development